Changing Trends in Diagnosis & Management of CLL - 25 sep 2020

Part 1 - Welcome and Introduction - Dr. Shweta Surve , AstraZeneca & Dr. M B Agarwal, Mumbai
Part 2 - Chief Guest's address - Dr. S H Advani, Mumbai
Part 3 - 2020 update on diagnosis / Risk stratification for CLL - Dr. Rahul Bhargava, Gurugram
Part 4 - Panel Discussion : Rationale for identifying HR group and testing platforms - Dr. Chezian
Part 5 - Debate: Which is the best Tx strategy? - Treat to progression vs. Finite Tx
Part 6 - Role of Rituximab in management of CLL in 2020 - Dr. Gaurav Prakash, Chandigarh
Part 7 - Treatment changes in the management of CLL due to COVID-19 - Dr. Kishore Kumar, Chennai
Part 8 - Clinical experience & challenges with Ibrutinib - Dr. Mallikarjuna Kalashetty, Bengaluru
Part 9 - Role of Acalabrutinib (2nd gen BTKI) in the management of CLL - Dr. Sameer Melinkeri, Pune
Part 10 - Panel Discussion - Newer approaches in the management of CLL - Dr. M B Agarwal
Part 11 - Closing Remarks - Dr. Shweta Surve , AstraZeneca